Panel rules against HRT for preventing chronic disease

October 22, 2012
by Kathleen Doheny, Healthday Reporter

Updated recommendations don't address relief of menopausal symptoms.

(HealthDay)—Postmenopausal women should not use hormone replacement therapy to prevent chronic medical conditions such as heart disease, according to updated recommendations from the U.S. Preventive Services Task Force.

For the update, published online Oct. 23 in the Annals of Internal Medicine, the independent panel of experts reviewed more than 50 articles published since 2002 about estrogen-progestin therapy and estrogen alone for prevention of heart disease, dementia, osteoporosis and other chronic conditions. It recommends against their use for all because of the increased risk of other conditions including stroke.

"The task force does not address treatment, so we do not make recommendations about menopausal symptoms," said Dr. Virginia Moyer, chair of the task force.

The report essentially echoes the task force's 2005 guidelines, while taking into account the more recent research. "It was updated as part of our routine to make sure the data were current," Moyer said.

The debate about the risks and harms of hormone therapy is ongoing. Years ago, hormone therapy was often prescribed to prevent chronic conditions such as osteoporosis and cardiovascular disease. But initial results of the Women's Health Initiative study, published in 2002, found harmful effects for estrogen-plus-progestin therapy. These included increased risk of heart disease and multiple other problems.

Two years later, serious concerns about estrogen-only therapy—often used after a hysterectomy— were also raised.

Here are highlights of the current report:

Although hormone therapy is of moderate benefit in reducing the risk of osteoporosis-related fractures, that benefit is outweighed by the harms, including an increased risk for stroke, gallbladder disease and urinary incontinence.

Convincing evidence connects hormone therapy with a small increased risk of breast cancer, and blood clots in the limbs and lungs.

Estrogen and progestin combined increased risk for probable dementia.

Hormone therapy appears to have no protective effect against heart disease and likely increases the risk, the task force said.

The updated recommendations are in line with those of many major health organizations, including the American Heart Association, the American Congress of Obstetricians and Gynecologists and the American Academy of Family Physicians.

One expert said the updated recommendations reflect current practice and won't change how he counsels patients.

"We currently aren't using it for chronic disease," said Dr. Michael Nimaroff, vice chair of obstetrics and gynecology at North Shore University Hospital of the LIJ Health System in Great Neck, N.Y., who was not involved with the report.

Related Stories

(HealthDay) -- Updated evidence on hormone replacement therapy for menopausal women presents good news for those at risk of osteoporosis, but a mixed bag of results regarding breast cancer and other chronic diseases.

The debate about using menopausal hormone therapies to relieve symptoms in post-menopausal women has been ongoing. Is the combination therapy of estrogen and progestin better or worse than just giving women estrogen alone? ...

After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal ...

Recommended for you

New genetic research from an international team including McMaster University, University of Helsinki, Vilnius University and the University of Sydney, suggests that smallpox, a pathogen that caused millions of deaths worldwide, ...

Psoriasis is well-known for causing too many skin cells on elbows, knees, and across the body, but people living with psoriasis may also be at an increased risk of heart disease. Effects of overactive immune cells in the ...

In a new study, researchers have modified a rabies virus, so that it has a protein from the MERS virus; this altered virus works as a 2-for-1 vaccine that protects mice against both Middle East Respiratory Syndrome (MERS) ...

Using state-of-the-art brain imaging technology, scientists at the National Institutes of Health filmed what happens in the brains of mice that developed cerebral malaria (CM). The results, published in PLOS Pathogens, reveal ...

0 comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.